138 related articles for article (PubMed ID: 37161855)
1. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K; Gaziano JM; Fillmore NR
Am J Hematol; 2023 Aug; 98(8):1214-1222. PubMed ID: 37161855
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
5. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
[No Abstract] [Full Text] [Related]
7. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System.
Martens KL; Li A; La J; May SB; Swinnerton KN; Tosi H; Elbers DC; Do NV; Brophy MT; Gaziano JM; Lotfollahzadeh S; Chitalia V; Ravid K; Fillmore NR
JAMA Netw Open; 2023 Jun; 6(6):e2317945. PubMed ID: 37306999
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.
Dutra B; Garcia-Rodriguez V; Garcia R; Szafron D; Abraham F; Khurana S; Lockhart J; Amin R; Wang Y; Thomas A
Am J Clin Oncol; 2023 Mar; 46(3):94-100. PubMed ID: 36735530
[TBL] [Abstract][Full Text] [Related]
13. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
[TBL] [Abstract][Full Text] [Related]
14. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
15. A Stitch in Time Saves Clots: Venous Thromboembolism Chemoprophylaxis in Traumatic Brain Injury.
Coleman JR; Carmichael H; Zangara T; Dunn J; Schroeppel TJ; Campion E; Goodman M; Hosokawa P; Sauaia A; Moore EE; Bunn B; Floren M; Ferrigno L
J Surg Res; 2021 Feb; 258():289-298. PubMed ID: 33039638
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
Front Oncol; 2022; 12():974227. PubMed ID: 36523994
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Cho YK; Kim YB
BMC Cancer; 2021 Oct; 21(1):1166. PubMed ID: 34717579
[TBL] [Abstract][Full Text] [Related]
18. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
[TBL] [Abstract][Full Text] [Related]
19. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
[TBL] [Abstract][Full Text] [Related]
20. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
Khorana AA; Dalal M; Lin J; Connolly GC
Cancer; 2013 Feb; 119(3):648-55. PubMed ID: 22893596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
